Riluzole has no acute effect on motor unit parameters in ALS

Journal of the Neurological Sciences

Volumn 160, Issue SUPPL. 1, 1998, Pages

  Desai, Joy ^a   Sharief, Mohamad ^a   Swash, Michael ^a  

^a ROYAL LONDON HOSPITAL   (United Kingdom)

Author keywords

Amyotrophic lateral sclerosis; Clinical trials; Motor unit potentials; Riluzole

Indexed keywords

RILUZOLE; SODIUM CHANNEL;

AMYOTROPHIC LATERAL SCLEROSIS; CHANNEL GATING; CONFERENCE PAPER; DRUG EFFECT; DRUG MECHANISM; HUMAN; MOTOR UNIT; PRIORITY JOURNAL;

AMYOTROPHIC LATERAL SCLEROSIS; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; ELECTROMYOGRAPHY; HUMANS; MEMBRANE POTENTIALS; MOTOR NEURONS; RILUZOLE;

EID: 0031755215     PISSN: 0022510X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-510X(98)00201-9     Document Type: Conference Paper

References (30)

1. Benavides J, Camelin JC, Mitran N, et al. 2-Amino-6-trifluoromethoxy benzothiazole, a possible antagonist of excitatory amino acid transmission-II: biochemical properties. Neuropharmacology 1985;24:1085-92.
2. Benoit E, Escande D. Riluzole specifically blocks inactivated Na channels in myelinated nerve fibre. Pflugers Arch 1991;419:603-9.
3. Bensimon G, Lacomblez L, Meininger V, ALS/Riluzole Study Group. A controlled trial of riluzole in amyotrophic lateral sclerosis. New Engl J Med 1994;330;585-91.
4. Bryson HM, Fulton B, Benfield P. Riluzole. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in amyotrophic lateral sclerosis. Drugs 1996;52:549-63.
5. Carvalho M, Swash M. Fasciculation potentials in amyotrophic lateral sclerosis and other neurogenic disorders: a comparative electrophysiological investigation. Muscle Nerve 1998;21:336-44.
6. Choi DW. Glutamate neurotoxicity and diseases of the nervous system. Neuron 1988;1:623-34.
7. Desai J, Swash M. Fasciculations: What do we know of their significance? J Neurol Sci 1997;152(Suppl. 1):S43-8.
8. Doble A. The pharmacology and mechanism of action of riluzole. Neurology 1996;47(Suppl 4):S233-41.
9. Drejer J, Honore T, Schousboe A. Excitatory amino acid-induced release of 3H-GABA from cultured mouse cerebral cortex interneurons. J Neurosci 1987;7:2910-8.
10. El Escorial World Federation. El Escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis. J Neurol Sci 1994;124;(Suppl.);96-107.
11. Estevez AG, Stutzmann JM, Barbeito L. Protective effect of riluzole on excitatory amino acid mediated neurotoxicity on motoneuron-enriched cultures. Eur J Pharmacol 1995;280:47-53.
12. Girdlestone D, Dupuy A, Coston A, et al. Riluzole antagonizes excitatory amino-acid-evoked firing in rat facial motoneurons invivo. Br J Pharmacol 1989;97(Suppl):583P.
13. Herbert T, Drapeau P, Pradier L, et al. Block of the rat brain IIA sodium channel alpha subunit by the neuroprotective drug riluzole. Mol Pharmacol 1994;45:1055-60.
14. Hubert JP, Delumeau JC, Glowinski J, et al. Antagonism by riluzole of entry of calcium evoked by NMDA and veratridine in rat cultured granule cells: evidence for a dual mechanism of action. Br J Pharmacol 1994;113:261-7.
15. Janko M, Trontelj JV, Gersak K. Fasciculations in motor neuron disease: discharge rate reflects extent and recency of collateral sprouting. J Neurol Neurosurg Psychiatry 1989;52:1375-81.
16. Koek W, Colpaert FC. Selective blockade of N-Methyl-D-Aspartate (NMDA)-induced convulsions by NMDA antagonists and putative glycine antagonists: Relationship with phencyclidine-like behavioral effects. J Pharamacol Exp Ther 1990;252:349-57.
17. Lacomblez L, Bensimon G, Leigh PN, ALS/Riluzole Study Group II. Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Lancet 1996;347;1425-31.
18. Plaitakis A, Caroscio JT. Abnormal glutamate metabolism in amyotrophic lateral sclerosis. Ann Neurol 1987;22:575-9.
19. Plaitakis A, Constantakakis E, Smith J. The neuroexcitotoxic amino acids glutamate and aspartate are altered in the spinal cord and brain in amyotrophic lateral sclerosis. Ann Neurol 1988;24:446-9.
20. Rhône-Poulenc Rorer. Riluzole prescribing information. Collegeville, PA, USA, 1996.
21. Rothstein JD, Martin LJ, Kuncl RW. Decreased glutamate transport by the brain and spinal cord in amyotrophic lateral sclerosis. New Engl J Med 1992;326:1464-8.
22. Rothstein JD. Excitotoxic mechanisms in the pathogenesis of amyotrophic lateral sclerosis. Adv Neurol 1995;68:7-20.
23. Rothstein JD, Van Kammen M, Levey AI, et al. Selective loss of glial glutamate transporter GLT-1 in amyotrophic lateral sclerosis. Ann Neurol 1995;38:73-84.
24. Shaw P. Excitotoxicity and motor neurone disease: a review of the evidence. J Neurol Sci 1994;124(Suppl):6-13.
25. Stalberg E. Electrophysiological studies of reinnervation in ALS. In: Rowland LP, editor. Human motor neuron diseases. New York: Raven Press, 1982:47-59.
26. Stalberg E, Sanders D. The motor unit in ALS studied with different neurophysiological techniques. In: Rose FC, editor. Research progress in motor neuron disease. London: Pitman, 1984:105-22.
27. Swash M, Schwartz MS. Staging motor neuron disease; single fibre EMG studies of asymmetry, progression and compensatory reinnervation. In: Rose FC, editor. Research progress in motor neuron disease. London: Pitman 1984:123-40.
28. Trojaborg W, Buchthal F. Malignant and benign fasciculations. Acta Neurol Scand 1965;41(Suppl 13):251-4.
29. Wagner ML, Landis BE. Riluzole: A new agent for amyotrophic lateral sclerosis. Ann Pharmacother 1997;31:738-43.
30. Van der Heijden A, Spaans F, Reulen J. Fasciculation potentials in foot and leg muscles of healthy young adults. Electroencephalogr Clin Neurophysiol 1994;93(3):163-8.